Sign In
Buy ARVN
$8.03
-0.270 (-3.25%)
At Close: Jul 31, 2026
BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Arvinas, Inc. (Nasdaq: ARVN) for potential securities law violations. Investors who have lost money in their Arvinas, Inc. inv
Arvinas, Inc. (ARVN) Q1 Earnings and Revenues Beat Estimates
09:15am, Thursday, 01'st May 2025
Arvinas, Inc. (ARVN) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of a loss of $0.86 per share. This compares to loss of $0.97 per share a year ago.
Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update
07:00am, Thursday, 01'st May 2025
– Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first-in-human data for the Company's first neuroscience program with AR
Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
07:00am, Monday, 28'th Apr 2025
NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation,
– ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard-of-care chemotherapy, biologics, and select investigational oral small mole
– Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial –
Company to highlight preclinical study of ARV-393, an investigational PROTAC BCL6 degrader, in combination with standard of care therapies Company to highlight preclinical study of ARV-393, an investi
After Plunging -25.42% in 4 Weeks, Here's Why the Trend Might Reverse for Arvinas (ARVN)
10:35am, Wednesday, 09'th Apr 2025
The heavy selling pressure might have exhausted for Arvinas (ARVN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in
Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study
03:38pm, Friday, 04'th Apr 2025
Arvinas, Inc. ARVN unveiled first-in-human data on Friday for its experimental Parkinson's disease treatment, ARV-102.
– Data demonstrate that ARV-102 was well tolerated, orally bioavailable, and brain-penetrant; ARV-102 achieved central and peripheral LRRK2 reduction indicating substantial LRRK2 protein degradatio
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer's & Parkinson's Diseases
07:00am, Thursday, 27'th Mar 2025
– Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose portions of a Phase 1 study of ARV-102, an investigational PROTAC LRRK2 de
Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround
10:35am, Wednesday, 19'th Mar 2025
Arvinas (ARVN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising e
Down -53.96% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround
10:35am, Monday, 17'th Mar 2025
The heavy selling pressure might have exhausted for Arvinas (ARVN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in
Arvinas (ARVN) Moves 8.8% Higher: Will This Strength Last?
11:55am, Thursday, 13'th Mar 2025
Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in th
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial
12:30pm, Tuesday, 11'th Mar 2025
Arvinas, Inc. ARVN and Pfizer Inc. PFE released topline results from the Phase 3 VERITAC-2 trial evaluating vepdegestrant monotherapy versus fulvestrant in adult patients with advanced or metastatic
